查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1391956

胰岛素增敏剂市场：按胰岛素增敏剂类型、按适应症、按给药途径、按配销通路、按地区

Insulin Sensitizers Market, By Type of Insulin Sensitizers, By Indication, By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球胰岛素增敏剂市场规模预计将从2023年的210亿美元增加到2030年的324.2亿美元，2023-2030年预测期间复合年增长率为6.4%。

报告范围 报告详情
基准年 2022年 2023年市场规模 210亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 6.40% 2030年市场规模预测 324.2亿美元
图 1. 2023 年胰岛素增敏剂的全球市场占有率（按地区划分）
胰岛素增敏剂市场-IMG1

胰岛素增敏剂是提高胰岛素敏感性和降低血糖值的药物。这些药物也被称为血糖正常剂或降血药，有助于在不使用胰岛素的情况下将血糖值恢復到正常范围。它们的作用是提高肝臟、肌肉和脂肪细胞对胰岛素的敏感性。胰岛素增敏剂有多种类型，包括二甲双胍 (Met)、吡格列酮 (Pio)、噻唑烷 (TZD) 和肌醇。

市场动态

全球胰岛素增敏剂市场的成长是由糖尿病（尤其是第2型糖尿病）盛行率不断上升所推动的。胰岛素增敏剂常用于治疗第 2 型糖尿病，以提高胰岛素敏感性并控制血糖值。肥胖会显着增加第 2 型糖尿病和胰岛素抗性。由于全球肥胖盛行率不断上升，有效的胰岛素增敏剂可以帮助控制与胰岛素抗性相关的代谢疾病。正在进行的研究和开发工作正在创造创新的化合物和配方，并推出新的和增强的胰岛素增敏剂，以提高治疗胰岛素敏感性的药物的功效和安全性。此外，各国政府也采取了多项倡议来对抗糖尿病。其计划和项目的重点是普及糖尿病知识、早期发现糖尿病以及推广胰岛素增敏剂等必要且负担得起的治疗方法。

与其他药物一样，胰岛素增敏剂也可能产生副作用，例如体重增加、体液储存、骨折和心臟衰竭风险增加。某些类别的胰岛素增敏药物，例如噻唑烷 (TZD)，可能会引起人们对其安全性的担忧，这限制了它们的使用，并使它们难以获得广泛接受。

本研究的主要特点

  • 本报告对全球胰岛素增敏剂市场进行了详细分析，并提出了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球胰岛素增敏剂市场的主要企业。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
  • 全球胰岛素增敏剂市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球胰岛素增敏剂市场的各种策略矩阵，将促进相关人员的决策。

目录

第1章调查目的和假设

  • 研究目标
  • 假设
  • 简称

第2章市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第3章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
  • 糖尿病盛行率增加
  • 肥胖流行病在全球日益严重
  • 药物开发的进展
  • 政府有利配合措施
    • 抑制因素
  • 副作用和安全问题
  • 对某些患者族群的疗效有限
  • 监管挑战和市场进入
    • 机会
  • 新兴国家
  • 个人化医疗
  • 联合治疗
  • 非糖尿病应用
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第4章全球胰岛素增敏剂市场 - 冠状冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第5章全球胰岛素增敏剂市场，依类型，2018-2030

  • 噻唑烷二酮 (TZD)
  • 双胍类
  • Incretin-based的治疗
  • 其他的

第6章全球胰岛素增敏剂市场，依适应症划分，2018-2030 年

  • 2型糖尿病
  • 糖尿病前期
  • 卵巢症候群（PCOS）

第7章全球胰岛素增敏剂市场，依给药途径，2018-2030

  • 口服
  • 注射

第8章全球胰岛素增敏剂市场，依配销通路，2018-2030

  • 医院药房
  • 零售药房
  • 线上药房

第9章2018-2030年全球胰岛素增敏剂市场（按地区）

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东和非洲
  • GCC
  • 以色列
  • 北非
  • 中部非洲
  • 其他中东和非洲

第10章竞争形势

  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Takeda Pharmaceutical

第11章章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6069

Global insulin sensitizers market size is projected to reach US$ 32.42 billion by 2030, from US$ 21.00 billion in 2023, at a CAGR of 6.4% during the forecast period 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 21.00 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.40% 2030 Value Projection: US$ 32.42 Bn
Figure 1. Global Insulin Sensitizers Market Share (%), By Region, 2023
Insulin Sensitizers Market - IMG1

Insulin sensitizers are medications that improve insulin sensitivity and reduce blood sugar levels. These are also known as blood sugar normalizing agents and euglycemics, and these help in returning blood glucose to the normal range without using insulin. These work by increasing liver, muscle and fat cells' sensitivity to insulin. There are several different types of insulin sensitizers including metformin (Met), pioglitazone (Pio), thiazolidinediones (TZDs), and inositols.

Market Dynamics

Global insulin sensitizers market growth is driven by increased prevalence of diabetes, especially type 2 diabetes. Insulin sensitizers are frequently used to increase insulin sensitivity and manage blood glucose levels in the treatment of type 2 diabetes. Type 2 diabetes and insulin resistance are both significantly increased by obesity. Effective insulin sensitizer helps in controlling insulin resistance and related metabolic diseases due to rising prevalence of obesity worldwide. The ongoing research and development activities have introduced new and enhanced insulin sensitizers that creates innovative compounds and formulation methods, and improves the efficacy and safety profiles of drugs that treat insulin sensitivity. Furthermore, the governments have taken several initiatives to combat diabetes. The plans and the programs focus on spreading knowledge about diabetes, early detection of diabetes and facilitating necessary and affordable treatments like insulin sensitizers.

Like any drugs, insulin sensitizers have potential side effects like weight gain, fluid retention, bone fractures, and an elevated risk of heart failure. Specific kinds of insulin sensitizers such as thiazolidinediones (TZDs) may create worries about its safety concern, thus, restricting their use and make them difficult to embrace widely.

Key features of the study:

  • This report provides in-depth analysis of the global insulin sensitizers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global insulin sensitizers market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global insulin sensitizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin sensitizers market

Insulin Sensitizers Market Detailed Segmentation:

  • By Type:
    • Thiazolidinediones (TZDs)
    • Biguanides
    • Incretin-based therapies
    • Others
  • By Indication:
    • Type 2 Diabetes
    • Prediabetes
    • Polycystic Ovary Syndrome (PCOS)
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East &Africa
  • Company Profiles:
    • Eli Lilly and Company
    • Novo Nordisk
    • Sanofi
    • Merck & Co.
    • Bristol Myers Squibb
    • AstraZeneca
    • Boehringer Ingelheim
    • Johnson & Johnson
    • Takeda Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Insulin Sensitizers
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing prevalence of diabetes
  • Growing global obesity epidemic
  • Advancements in drug development
  • Favorable government initiatives
    • Restraints
  • Adverse effects and safety concerns
  • Limited efficacy in certain patient populations
  • Regulatory challenges and market access
    • Opportunities
  • Emerging economies
  • Personalized medicine
  • Combination therapies
  • Non-diabetic applications
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Insulin Sensitizers Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Insulin Sensitizers Market, By Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Thiazolidinediones (TZDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Biguanides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Incretin-based therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Insulin Sensitizers Market, By Indication, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Type 2 Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn )
  • Prediabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Polycystic Ovary Syndrome (PCOS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Insulin Sensitizers Market, By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Insulin Sensitizers Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Insulin Sensitizers Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • North Africa
  • Central Africa
  • Rest of Middle East & Africa

10. Competitive Landscape

  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us